Mutation or loss of p53 differentially modifies TGFβ action in ovarian cancer.
Ovarian cancer is the most lethal gynecological disease affecting women in the US. The Cancer Genome Atlas Network identified p53 mutations in 96% of high-grade serous ovarian carcinomas, demonstrating its critical role. Additionally, the Transforming Growth Factor Beta (TGFβ) pathway is dysfunction...
Guardado en:
Autores principales: | Eoghainín Ó hAinmhire, Suzanne M Quartuccio, Whay Cheng, Roshan A Ahmed, Shelby M King, Joanna E Burdette |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f96d07137ceb4af39b4e4d5c53e1082f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The action of ovarian hormones in cardiovascular disease
por: MEDINA,RODOLFO A, et al.
Publicado: (2003) -
nc886 is induced by TGF-β and suppresses the microRNA pathway in ovarian cancer
por: Ji-Hye Ahn, et al.
Publicado: (2018) -
Expression of Fbxo7 in haematopoietic progenitor cells cooperates with p53 loss to promote lymphomagenesis.
por: Mikhail Lomonosov, et al.
Publicado: (2011) -
Author Correction: nc886 is induced by TGF-β and suppresses the microRNA pathway in ovarian cancer
por: Ji-Hye Ahn, et al.
Publicado: (2018) -
Canine tumor mutational burden is correlated with TP53 mutation across tumor types and breeds
por: Burair A. Alsaihati, et al.
Publicado: (2021)